Shanghai Medicilon Inc
SSE:688202
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (3.5), the stock would be worth ¥56.21 (11% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 4 | ¥63.26 |
0%
|
| 3-Year Average | 3.5 | ¥56.21 |
-11%
|
| 5-Year Average | 5.3 | ¥84.12 |
+33%
|
| Industry Average | 2.7 | ¥42.59 |
-33%
|
| Country Average | 1.9 | ¥30.67 |
-52%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shanghai Medicilon Inc
SSE:688202
|
8.5B CNY | 4 | -36.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 84.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
174.4B USD | 1.9 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
124B USD | 1.8 | 33.6 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 5.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 2 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.4B USD | 3.2 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.1B USD | 7 | 46.9 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.8B USD | 1.6 | 19.8 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.8B USD | 8.2 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Shanghai Medicilon Inc
Glance View
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. The company is headquartered in Shanghai, Shanghai and currently employs 2,440 full-time employees. The company went IPO on 2019-11-05. The firm is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The firm's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The firm provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
